Project Details
Description
"Investigation of protective mechanisms of monoclonal antibodies against SARS-CoV-2"
Sponsor will provide UTMB with the following materials:
Up to 15 monoclonal antibodies, up to 500 micrograms for each antibody
UTMB will perform the following tasks:
1. Authentic virus neutralization assays with current and future variants of SARSCoV-2 for potency testing of our lead molecules as well as next-generation molecules in stable, qualified assays. Pilot studies to assess the neutralization assay: Focus reduction neutralization test (FRNT) assays will be carried out for designated antibodies over the course of the Research Program. The assay will be performed in triplicate for each isolate with 3 replicates. The data will be
analyzed and shared with the Sponsor.
• The University will communicate with the Sponsor of new variants in their possession, and the studies outlined in #1 will be performed to evaluate the new variant against designated antibodies. UTMB will await confirmation from the Sponsor before evaluating a new variant against designated antibodies.
• During the Term of the Agreement, up to 10 new variants will be evaluated as part of the pilot study.
2. As resources (e.g. budget, time, effort) allow and as reasonably requested by Sponsor, UTMB will expand scientific understanding and be thought-leaders of SARS-CoV-2 infections with particular focus on host-pathogen interactions, immune regulation/dysregulation, antibody-responses to infection in humans (and potentially translational animal models), and the contribution of virulence neutralization.
Status | Finished |
---|---|
Effective start/end date | 9/1/23 → 8/31/24 |
Funding
- Invivyd ( Award # ): $202,397.00